Effects of herbal Epimedium on the improvement of bone metabolic disorder through the induction of osteogenic differentiation from bone marrow-derived mesenchymal stem cells
| Autor: | Mun Seog Chang, Ji Eun Lee, Ho Chul Lee, Do Rim Kim, Kyung Jun Shim, Jin Hyoung Cho, Seong Kyu Park |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_specialty Cell Osteoporosis osteogenic differentiation Biochemistry Bone remodeling Mice 03 medical and health sciences 0302 clinical medicine Osteogenesis Proliferating Cell Nuclear Antigen Internal medicine Genetics medicine Animals Molecular Biology Cell Proliferation Epimedium Herbal Epimedium biology Mesenchymal stem cell apoptosis Cell Differentiation Mesenchymal Stem Cells Articles Cell cycle medicine.disease osteoporosis Proliferating cell nuclear antigen Mice Inbred C57BL 030104 developmental biology medicine.anatomical_structure Endocrinology Oncology Apoptosis mouse bone marrow mesenchymal stem cells 030220 oncology & carcinogenesis biology.protein Cancer research Molecular Medicine Bone marrow Drugs Chinese Herbal |
| Zdroj: | Molecular Medicine Reports |
| ISSN: | 1791-3004 1791-2997 |
| DOI: | 10.3892/mmr.2016.6015 |
| Popis: | Herbal Epimedium (HE) has been commonly used as a tonic, antirheumatic agent and in the treatment of bone‑associated diseases including osteoporosis. Treatment for osteoporosis is important to increase bone mass density and maintain to balance of bone remodeling. The present study was performed to investigate the effects of HE on mouse bone marrow mesenchymal stem cell (mBMMSC) proliferation and osteogenic differentiation, using MTT assays, proliferating cell nuclear antigen (PCNA) detection and apoptosis and differentiation assays. HE was demonstrated to inhibit the proliferation of mBMMSCs up to 45.43±3.33% and to decrease the level of PCNA expression compared with untreated cells. HE also induced late apoptosis at 24 and 48 h after treatment up to 71.93 and 67.03%, respectively, while only 14.93% of untreated cells exhibited apoptosis. By contrast, HE induced differentiation of mBMMSCs into an osteogenic lineage at the beginning of three weeks after commencement of treatment. This suggested that HE is a candidate as an inducer of osteogenesis from bone marrow mesenchymal stem cells, and additionally has potential for use in the treatment of bone metabolic disorders such as osteoporosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|